Sinovac PCV13

**Sinovac PCV13** is Sinovac Life Sciences' investigational 13-valent pneumococcal polysaccharide conjugate vaccine for prevention of pneumococcal disease caused by *Streptococcus pneumoniae*. The vaccine is designed to induce active, serotype-specific immune responses against pneumococcal capsular polysaccharide antigens through conjugate-vaccine immunization. It has been evaluated in pediatric populations, including infants and children through 5 years of age; registered Sinovac-sponsored studies include Phase 1b and Phase 3 trials assessing safety and immunogenicity. ([clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06183216))

Brand names

iPneucia

Other names

Sinovac 13-valent pneumococcal polysaccharide conjugate vaccineSinovac13-valent pneumococcal polysaccharide conjugate vaccineSinovac-13-valent pneumococcal polysaccharide conjugate vaccineSinovac 13-valent pneumococcal conjugate vaccineSinovac13-valent pneumococcal conjugate vaccineSinovac-13-valent pneumococcal conjugate vaccine